JPWO2005094894A1 - 細胞に核酸を導入するための製剤 - Google Patents

細胞に核酸を導入するための製剤 Download PDF

Info

Publication number
JPWO2005094894A1
JPWO2005094894A1 JP2006511825A JP2006511825A JPWO2005094894A1 JP WO2005094894 A1 JPWO2005094894 A1 JP WO2005094894A1 JP 2006511825 A JP2006511825 A JP 2006511825A JP 2006511825 A JP2006511825 A JP 2006511825A JP WO2005094894 A1 JPWO2005094894 A1 JP WO2005094894A1
Authority
JP
Japan
Prior art keywords
cells
nucleic acid
pullulan
spermine
cationized
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006511825A
Other languages
English (en)
Japanese (ja)
Inventor
田畑　泰彦
泰彦 田畑
Original Assignee
株式会社メドジェル
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 株式会社メドジェル filed Critical 株式会社メドジェル
Publication of JPWO2005094894A1 publication Critical patent/JPWO2005094894A1/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B35/00—Preparation of derivatives of amylopectin
    • C08B35/04—Ethers
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0018—Pullulan, i.e. (alpha-1,4)(alpha-1,6)-D-glucan; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0021—Dextran, i.e. (alpha-1,4)-D-glucan; Derivatives thereof, e.g. Sephadex, i.e. crosslinked dextran
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08H—DERIVATIVES OF NATURAL MACROMOLECULAR COMPOUNDS
    • C08H1/00—Macromolecular products derived from proteins
    • C08H1/06—Macromolecular products derived from proteins derived from horn, hoofs, hair, skin or leather
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L3/00—Compositions of starch, amylose or amylopectin or of their derivatives or degradation products
    • C08L3/14—Amylose derivatives; Amylopectin derivatives
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/02—Dextran; Derivatives thereof

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Materials Engineering (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2006511825A 2004-03-31 2005-03-31 細胞に核酸を導入するための製剤 Pending JPWO2005094894A1 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2004103568 2004-03-31
JP2004103568 2004-03-31
PCT/JP2005/006370 WO2005094894A1 (ja) 2004-03-31 2005-03-31 細胞に核酸を導入するための製剤

Publications (1)

Publication Number Publication Date
JPWO2005094894A1 true JPWO2005094894A1 (ja) 2008-02-14

Family

ID=35063541

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006511825A Pending JPWO2005094894A1 (ja) 2004-03-31 2005-03-31 細胞に核酸を導入するための製剤

Country Status (4)

Country Link
US (1) US20090117657A1 (de)
EP (1) EP1738769A4 (de)
JP (1) JPWO2005094894A1 (de)
WO (1) WO2005094894A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007117054A (ja) * 2005-10-31 2007-05-17 Medgel Corp 核酸とカチオン化多糖とのポリイオンコンプレックスを用いるリバーストランスフェクション
MX351599B (es) * 2012-03-15 2017-10-20 Acraf Polimeros cationicos con base en glucogeno.
CA2931862C (en) 2013-11-08 2024-01-23 Carlos Filipe Method of stabilizing molecules without refrigeration using water soluble polymers and applications thereof in performing chemical reactions
CN113786392A (zh) * 2021-09-30 2021-12-14 四川大学 一种纳米颗粒及其制备方法和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001199903A (ja) * 1999-11-09 2001-07-24 Eizo Mori 核酸含有複合体
WO2002072152A1 (fr) * 2001-03-13 2002-09-19 Japan Science And Technology Corporation Supports de gene mettant en oeuvre un polysaccharide et leur procede de production
JP2002272470A (ja) * 2001-03-21 2002-09-24 Takashi Nakamura リジルオキシダーゼ関連タンパク質をコードする核酸
JP2003104914A (ja) * 2001-09-28 2003-04-09 Yasuhiko Tabata Ｄｎａ−金属−水溶性高分子複合体

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001199903A (ja) * 1999-11-09 2001-07-24 Eizo Mori 核酸含有複合体
WO2002072152A1 (fr) * 2001-03-13 2002-09-19 Japan Science And Technology Corporation Supports de gene mettant en oeuvre un polysaccharide et leur procede de production
JP2002272470A (ja) * 2001-03-21 2002-09-24 Takashi Nakamura リジルオキシダーゼ関連タンパク質をコードする核酸
JP2003104914A (ja) * 2001-09-28 2003-04-09 Yasuhiko Tabata Ｄｎａ−金属−水溶性高分子複合体

Also Published As

Publication number Publication date
WO2005094894A1 (ja) 2005-10-13
US20090117657A1 (en) 2009-05-07
EP1738769A4 (de) 2011-03-09
EP1738769A1 (de) 2007-01-03

Similar Documents

Publication Publication Date Title
Huh et al. Polysaccharide-based nanoparticles for gene delivery
Oh et al. Target specific and long-acting delivery of protein, peptide, and nucleotide therapeutics using hyaluronic acid derivatives
Gao et al. Arginine-chitosan/DNA self-assemble nanoparticles for gene delivery: In vitro characteristics and transfection efficiency
Rekha et al. Pullulan as a promising biomaterial for biomedical applications: a perspective
Gustafson et al. Silk-elastinlike protein polymers for matrix-mediated cancer gene therapy
KR101179471B1 (ko) 자기 집합체 고분자 나노입자를 이용한 ｓｉＲＮＡ 전달 시스템
Kim et al. Protein-resistant, reductively dissociable polyplexes for in vivo systemic delivery and tumor-targeting of siRNA
CN113786498A (zh) 通过递送bmp编码rna诱导骨生成
KR20140119513A (ko) 히알루론산을 포함하는 핵산전달용 조성물
EP2070970B1 (de) Transfektionsreagens
CN105793345B (zh) 双重衍生化壳聚糖纳米颗粒及制备方法和使用其体内基因转移的方法
CA2994809A1 (en) Silica-based biomolecule carrier, pharmaceutical composition comprising the same, preparation method and use thereof
CN108339124B (zh) 一种双级脑靶向聚合物胶束递药系统的制备方法和应用
JPWO2005094894A1 (ja) 細胞に核酸を導入するための製剤
US9572895B2 (en) Multiplexed supramolecular assemblies for non-viral delivery of genetic material
Kumari et al. Polysaccharide-based nanogels for drug and gene delivery
CN106727323B (zh) 一种透明质酸纳米囊泡及其制备方法和应用
Zhang et al. A zwitterionic polymer-inspired material mediated efficient CRISPR-Cas9 gene editing
EP2907876B1 (de) Reduktionsstimulusreaktives genvektorsystem und herstellung und verwendung davon
Park et al. Optimized Design of Hyaluronic Acid–Lipid Conjugate Biomaterial for Augmenting CD44 Recognition of Surface-Engineered NK Cells
JP6868306B2 (ja) 細胞導入剤
Zhang et al. Aminated yeast β-D-glucan for macrophage-targeted delivery of CpG oligodeoxynucleotides and synergistically enhanced cancer immunotherapy
Yadav et al. Marine biopolymers for gene delivery
KR101357899B1 (ko) 간세포 표적 유전자 전달체로서 갈락토실화 폴리에틸렌글리콜-키토산-그라프트-스페르민 공중합체 및 이를 이용한 유전자 치료
KR101841111B1 (ko) 히알루론산 유도체 및 이를 이용한 세포 표면 개질용 조성물

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080110

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110510

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20111101